# Colgate-Palmolive Company (CL)

> Source: Nexqual · https://nexqual.com/CL · data as of 2026-10-22 20:00 UTC · cite as "Nexqual, Colgate-Palmolive Company (CL), nexqual.com/CL" · informational, not investment advice.

**Price:** USD 97.39 (+4.27% on the day) · last close of Oct 22, 2026; US market pre market, not a live price. Prev close 93.4 · day 94.56–97.5 · 52w 74.55–99.33 · market cap $77.6B · NYQ

## Key facts
- Last four reported quarters (through Jun 30, 2026): revenue $21.0B, net income $2.04B (9.7% margin), free cash flow $3.86B (SEC filings).
- Valuation: P/E 38.1x (avg 28.2x at the last 3 fiscal year-ends).
- 4 of 80 tracked superinvestors hold CL (13F, Q2 2026): 0 new, 2 added, 1 reduced, 1 unchanged.
- Analysts: Buy (mean 2.10 on a 1–5 scale) (21 analysts), mean target USD 98.15 (range 87–110).
- Total return with dividends: 1Y +27.1% vs S&P 500 +14.9%; 5Y +45.3% vs S&P 500 +80.3%.
- Next earnings: 2026-10-30, EPS estimate USD 0.93, revenue estimate $5.33B.

## Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters)
| USD | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | TTM |
|---|---|---|---|---|---|---|
| Revenue | $17.4B | $18.0B | $19.5B | $20.1B | $20.4B | $21.0B |
| Gross profit | $10.4B | $10.2B | $11.3B | $12.2B | $12.3B | — |
| Operating income | $3.33B | $2.89B | $3.98B | $4.27B | $3.31B | $3.13B |
| Net income | $2.17B | $1.78B | $2.30B | $2.89B | $2.13B | $2.04B |
| EPS (diluted) | $2.55 | $2.13 | $2.77 | $3.51 | $2.63 | — |
| Free cash flow | $2.76B | $1.86B | $3.04B | $3.55B | $3.63B | $3.86B |
| Gross margin | 59.6% | 57.0% | 58.2% | 60.5% | 60.1% | — |
| Operating margin | 19.1% | 16.1% | 20.5% | 21.2% | 16.2% | 14.9% |
| Net margin | 12.4% | 9.9% | 11.8% | 14.4% | 10.5% | 9.7% |
| Revenue growth | +5.8% | +3.1% | +8.3% | +3.3% | +1.4% | — |
| Cash + short-term investments | $832M | $775M | $1.15B | $1.26B | $1.40B | — |
| Total debt | $7.21B | $8.76B | $8.24B | $7.94B | $7.99B | — |
Fiscal years end Dec. EPS is split-adjusted.

## Valuation (price ÷ last four quarters, through Jun 30, 2026)
P/E 38.1x · P/S 3.7x · P/FCF 20.1x · P/B 329.0x · FCF yield 4.97% · Earnings yield 2.62% · Buyback yield (TTM) 1.66%
P/E at fiscal year-ends: Dec 2025 30.1x, Dec 2024 25.9x, Dec 2023 28.7x.

## Superinvestors (SEC 13F-HR, Q2 2026)
4 of 80 tracked investors hold CL. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| First Eagle Investment | First Eagle Investment Management | 1.26% | $752M | Added +1.1% |
| Yacktman Asset Management |  | 0.90% | $72.5M | Added +0.2% |
| Jensen Investment Management |  | 0.26% | $10.6M | Reduced -2.9% |
| Dodge & Cox Funds | Dodge & Cox | <0.01% | $1.3M | Unchanged |

## Analysts
Consensus Buy (mean 2.10 on a 1–5 scale), 21 analysts; mean target USD 98.15 (low 87, high 110).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-19 | JP Morgan | Target raised | Overweight | $103 → $104 |
| 2026-10-05 | Wells Fargo | Target lowered | Equal-Weight | $95 → $90 |
| 2026-09-21 | Piper Sandler | Target lowered | Overweight | $98 → $95 |
| 2026-09-08 | RBC Capital | Reiterated | Outperform | $104 |
| 2026-08-03 | UBS | Target raised | Buy | $106 → $109 |
| 2026-08-03 | TD Cowen | Target raised | Hold | $85 → $90 |
| 2026-08-03 | JP Morgan | Target lowered | Overweight | $104 → $103 |
| 2026-08-03 | RBC Capital | Target raised | Outperform | $102 → $104 |
| 2026-08-03 | Evercore ISI Group | Target raised | Outperform | $100 → $101 |
| 2026-07-21 | Barclays | Target raised | Equal-Weight | $80 → $87 |
| 2026-07-16 | JP Morgan | Target raised | Overweight | $96 → $104 |
| 2026-07-16 | UBS | Target raised | Buy | $100 → $106 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-23) | 5Y (from 2021-10-18) |
|---|---|---|
| Total return | +27.1% | +45.3% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +27.2% | +7.7% |
| Volatility (annualized) | 22.9% | 17.9% |
| Max drawdown | -17.0% (Feb 2026→Apr 2026) | -26.5% (Sep 2024→Oct 2025) |

## Peers (Household & Personal Products)
UL (Unilever PLC) USD 67 +4.04% · EL (Estee Lauder Companies, Inc. (T) USD 107.72 +3.92% · KVUE (Kenvue Inc.) USD 19.88 +4.41% · KMB (Kimberly-Clark Corporation) USD 112.32 +5.32% · CHD (Church & Dwight Company, Inc.) USD 108.86 +3.68% · PG (Procter & Gamble Company (The)) USD 165.59 +5.58%

## More
Full page: https://nexqual.com/CL · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt

## Revenue by business segment (quarter ended 2026-06-30)

| Line | Revenue | Share | YoY | Operating income | Op. margin |
|---|---|---|---|---|---|
| Oral, Personal and Home Care | $4.17B | 77.7% | +5.4% | $1.08B | 26.0% |
| Hill's Pet Nutrition | $1.20B | 22.3% | +3.3% | $269.0M | 22.5% |
| Corporate costs (not allocated) | — | — | — | -$335.0M | — |
| Total revenue | $5.36B | 100% | — | $1.02B | 19.0% |

## Customer concentration

Period ended 2025-12-31: 11% of revenue from unnamed direct customers (10-K, filed 2026-02-23).

## Analyst estimates and revisions

| Period | EPS est. | 90d ago | Change | Revenue est. | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends 2026-09-30) | $0.93 | $0.92 | +0.3% | $5.33B | 17 |
| Next quarter (ends 2026-12-31) | $0.96 | $0.96 | +0.3% | $5.40B | 17 |
| Current fiscal year (ends 2026-12-31) | $3.87 | $3.81 | +1.4% | $21.40B | 20 |
| Next fiscal year (ends 2027-12-31) | $4.09 | $4.05 | +0.8% | $22.06B | 20 |

## Options: expected move (Cboe, 15-min delayed)

Expected move by 2026-10-30 (includes earnings 2026-10-30): ±3.8%; last 8 reports averaged ±2.9%.

| Expiration | Days | ATM IV | Expected move |
|---|---|---|---|
| 2026-10-30 | 7 | 32.2% | ±3.8% |
| 2026-11-06 | 14 | 25.1% | ±4.1% |
| 2026-11-13 | 21 | 25.8% | ±5.1% |
| 2026-11-20 | 28 | 24.0% | ±5.4% |
| 2026-11-27 | 35 | 23.1% | ±5.8% |
| 2026-12-04 | 42 | 22.8% | ±6.3% |
| 2026-12-18 | 56 | 22.7% | ±7.2% |
| 2027-01-15 | 84 | 21.2% | ±8.2% |